替雷利珠单抗联合注射用培美曲塞二钠+铂剂化疗对晚期非鳞非小细胞肺癌患者预后的影响  

The Effect of Temrelizumab Combined with Pemetrexed Disodium for In⁃jection+Platinum Chemotherapy on the Prognosis of Patients with Ad⁃vanced Non-squamous Non-small Cell Lung Cancer

作　　者：李双佐 LI Shuangzuo(Department of Oncology,Xinxing County People's Hospital,Yunfu 527400,Guangdong,China)

机构地区：[1]新兴县人民医院肿瘤科,广东云浮527400

出　　处：《系统医学》2024年第20期162-165,共4页Systems Medicine

摘　　要：目的分析驱动基因阴性晚期非鳞非小细胞肺癌患者治疗过程中采用替雷利珠单抗联合注射用培美曲塞二钠+铂剂化疗对于改善患者预后的价值。方法非随机选取新兴县人民医院肿瘤科于2020年1月—2023年1月收治的30例驱动基因阴性晚期非鳞非小细胞肺癌患者为研究对象,根据治疗方式不同分为对照组和观察组,各15例。对照组采用培美曲塞二钠+铂剂化疗,观察组采用替雷利珠单抗注射液联合注射用培美曲塞二钠+铂剂化疗,对比两组近期肿瘤治疗效果、肿瘤标志物水平、半年生存率。结果观察组的近期治疗总有效率为93.33%(14/15),高于对照组的60.00%(9/15),差异有统计学意义(P=0.043)。治疗后,观察组的肿瘤标志物水平均低于对照组,差异有统计学意义(P均<0.05)。观察组的半年生存率高于对照组,差异有统计学意义(P<0.05)。结论给予替雷利珠单抗联合注射用培美曲塞二钠+铂剂化疗治疗可有效延长驱动基因阴性晚期非鳞非小细胞肺癌患者生存期。Objective To analyze the value of terelizumab combined with pemetrexed disodium for injection+plati⁃num chemotherapy in improving the prognosis of patients with driver gene negative advanced non-squamous nonsmall cell lung cancer.Methods A total of thirty patients with driver gene negative advanced non-squamous nonsmall cell lung cancer admitted to the Department of Oncology of Xinxing County People's Hospital from January 2020 to January 2023 were non-randomly selected as the research objects.According to different treatment methods,they were divided into control group and observation group,with fifteen cases in each group.The control group was treated with pemetrexed disodium+platinum chemotherapy,and the observation group was treated with tirelizumab in⁃jection combined with pemetrexed disodium+platinum chemotherapy.The short-term tumor treatment effect,tumor marker level and half-year survival rate were compared between the two groups.Results The total effective rate of short-term treatment in the observation group was 93.33%(14/15),which was higher than 60.00%(9/15)in the con⁃trol group,and the difference was statistically significant(P=0.043).After treatment,the levels of tumor markers in the observation group were lower than those in the control group,and the differences were statistically significant(both P<0.05).The half-year survival rate of the observation group was higher than that of the control group,and the difference was statistically significant(P<0.05).Conclusion The treatment of terelizumab combined with pemetrexed disodium for injection+platinum chemotherapy can effectively prolong the survival time of driver gene negative advanced nonsquamous non-small cell lung cancer patients.

关 键 词：肺癌 非鳞非小细胞肺癌 替雷利珠单抗 注射用培美曲塞二钠 铂剂化疗 生存期 

分 类 号：R563[医药卫生—呼吸系统]